GAGs-Potentiated Inhibition of Thrombin, Factor Xa and Plasmin in Plasma and in a Purified System Containing Antithrombin III – Correlation with Total Charge Density

Summary The ability of heparin and related glycosaminoglycans (GAGs) to accelerate the inhibition of thrombin, factor Xa and plasmin in plasma and in a purified system containing antithrombin III (At III) was studied using chromogenic peptide substrate assays There was a good correlation between the charge density of the mucopolysaccharides and the activities investigated. While the difference between potentiation of the antithrombin activity by GAGs in plasma and in the purified system was slight, the inhibition of factor Xa in plasma was more pronounced than in the presence of purified At III, indicating the mechanisms for GAGs-potentiated inhibition of thrombin and factor Xa are not identical. For the antiplasmin activity, there was a good correlation between the chemical structure and biological activity only in the pure system, confirming that the antithrombin-GAG complex plays a very limited role in the inactivation of plasmin in plasma.

[1]  I. Danishefsky,et al.  Differential effect of high affinity heparin and low affinity heparin on methylene blue titration. , 1981, Thrombosis research.

[2]  W. Long,et al.  The anticoagulant activity of dermatan sulphates. , 1980, Thrombosis research.

[3]  E. A. Johnson,et al.  Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. , 1979, Thrombosis research.

[4]  F. Radaelli,et al.  Correlation of sulfate content and degree of carboxylation of heparin and related glycosaminoglycans with anticomplement activity. Relationships to the anticoagulant and platelet-aggregating activities. , 1979, Thrombosis research.

[5]  N. Aoki,et al.  Assay of alpha2-plasmin inhibitor activity by means of a plasmin specific tripeptide substrate. , 1978, Thrombosis research.

[6]  M. Verstraete,et al.  Inhibition of Plasmin by Antithrombin‐Heparin Complex , 1978, British journal of haematology.

[7]  A. Teger‐Nilsson,et al.  Determination of a new rapid plasmin inhibitor in human blood by means of a plasmin specific tripeptide substrate. , 1977, Scandinavian journal of clinical and laboratory investigation.

[8]  R. Rosenberg.  Biologic actions of heparin. , 1977, Seminars in hematology.

[9]  J. Hopwood,et al.  Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin , 1976, FEBS letters.

[10]  U. Abildgaard,et al.  The anticoagulant effect of heparan sulfate and dermatan sulfate. , 1976, Thrombosis research.

[11]  O. Odegård,et al.  Antifactor Xa activity measured with amidolytic methods. , 1976, Haemostasis.

[12]  O. Odegård,et al.  Heparin cofactor activity measured with an amidolytic method. , 1975, Thrombosis research.

[13]  O. Odegård.  Evaluation of an amidolytic heparin cofactor assay method. , 1975, Thrombosis research.

[14]  J. A. Cifonelli.  The relationship of molecular weight, and sulfate content and distribution to anticoagulant activity of heparin preparations. , 1974, Carbohydrate research.